Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.

By S. Hetherington, A. Hughes, M. Mosteller, Denise D Shortino, K. Baker, W. Spreen, E. Lai, Kirstie Davies, A. Handley, D. Dow and 5 more. The Lancet, 2002

815 citations recorded by the source corpus.

Subfields: Dermatology, Pharmacology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/ed687d48b2b9e5f3be97100c977e663fa249d899

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pharmacology

1. M. Eichelbaum
2. Magnus Ingelman-Sundberg
3. William E. Evans
4. Shufeng Zhou

Citations in the corpus

• HLA-A★3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans (2011, background): “The most prominent example thus far is the strong predictive value of the HLA-B*5701 allele for hypersensitivity to the drug abacavir, used for the treatment of human immunodeficiency virus infection.(25,26,29) FDA guidelines now recommend HLA-B*5701 testing in advance of abacavir prescription.”
• Pharmacogenomics and individualized drug therapy. (2006, background): “Indeed, genetic susceptibility is implicated in various idiosyncratic ADRs, including hypersensitivity to abacavir (9), Stevens-Johnson syndrome induced by carbamazepine (10), and severe cutaneous ADRs caused by allopurinol (11).”
• HIBAG – HLA Genotype Imputation with Attribute Bagging (2013, positive): “27 HLA alleles are associated with some of the strongest adverse drug reactions, for example, B*57:01 with Abacavir, which is used to treat HIV and AIDS, 28 and B*58:01 with Allopurinol used primarily to treat hyperuricemia.”